The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Rare Biomarkers Specimen Collection And Stabilization Market From 2026 To 2030?
The rare biomarkers specimen collection and stabilization market size has seen rapid growth in recent years. It is anticipated to expand from $35.29 billion in 2025 to $38.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. The historical period’s growth can be attributed to an increase in molecular diagnostics research, the expansion of oncology biomarker studies, the availability of plasma-based testing methods, heightened clinical trial activity, and the growing implementation of biobanking practices.
The rare biomarkers specimen collection and stabilization market is poised for robust expansion over the coming years. By 2030, its valuation is projected to reach $55.35 billion, demonstrating a compound annual growth rate (CAGR) of 9.2%. This anticipated growth during the forecast period stems from factors such as the heightened embrace of precision diagnostics, an escalating need for timely disease identification, the broader application of genomic and transcriptomic testing, increasing capital expenditure in drug development guided by biomarkers, and the greater incorporation of AI into biomarker analysis. Key developments expected in the forecast period encompass the wider acceptance of liquid biopsy collection methods, increased deployment of sophisticated stabilization reagents, a heightened necessity for preserving high-sensitivity biomarkers, the broadening scope of non-invasive diagnostic uses, and a reinforced emphasis on the integrity and traceability of samples.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp
Which Drivers Are Supporting The Rare Biomarkers Specimen Collection And Stabilization Market Growth?
The rising incidence of cancer is anticipated to fuel the expansion of the rare biomarker specimen collection and stabilization market in the future. Cancer encompasses a diverse range of illnesses marked by the uncontrolled multiplication and dissemination of atypical cells. This uptick in cancer cases stems from elements like environmental factors, lifestyle choices such as tobacco use and unhealthy eating, and inherited predispositions, collectively intensifying the demand for accurate diagnostic and monitoring instruments. The collection and stabilization of rare biomarker specimens are crucial for ensuring the precise preservation of blood- and tissue-derived biomarkers, which are essential for early diagnosis, molecular analysis, and treatment selection in oncology. A notable example comes from February 2024, when the World Health Organization, an intergovernmental entity based in Switzerland, forecast over 35 million new cancer diagnoses by 2050, marking a 77% rise from the approximately 20 million cases recorded in 2022. Consequently, the escalating incidence of cancer is propelling the growth of the rare biomarker specimen collection and stabilization market.
How Is Segmentation Applied In The Rare Biomarkers Specimen Collection And Stabilization Market Segment Analysis?
The rare biomarkers specimen collection and stabilization market covered in this report is segmented –
1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum
Which Trends Are Expected To Impact The Rare Biomarkers Specimen Collection And Stabilization Market?
Leading companies in the rare biomarkers specimen collection and stabilization market are prioritizing the development of advanced solutions, such as automated plasma and cell sample processing, to maintain biomarker integrity and enable high-throughput multiomics. Automated pre-analytical platforms refer to technologies that standardize the processing of blood samples like plasma separation, cell fixation, and slide preparation directly at the point of collection, ensuring consistent specimen quality without manual handling or specialized tubes. For instance, in April 2024, Tethis S.p.A., an Italy-based biotechnology company, announced the enrollment of its first two patients in a clinical study for its See.d platform. This platform automates standardized plasma and cell sample preparation for multiomic liquid biopsy, including the fixation of rare circulating tumor and immune cells on nanocoated SmartBioSurface slides. Designed to maximize sample integrity and facilitate seamless analysis of cell-free DNA and circulating tumor cells from a single draw, the platform supports the entire workflow of rare biomarker specimen collection and stabilization.
Who Are The Companies Participating In The Rare Biomarkers Specimen Collection And Stabilization Market Environment?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC
Get The Full Rare Biomarkers Specimen Collection And Stabilization Market Report:
Which Region Is The Leading Market For The Rare Biomarkers Specimen Collection And Stabilization Market?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Rare Biomarkers Specimen Collection And Stabilization Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2026, By The Business Research Company
Blood Transfusion Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report
Hematology Diagnostic Devices And Equipment Market Report
Immunochemistry Diagnostic Devices And Equipment Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model